The testing for COVID-19 in symptomatic patients as a protective factor against stress, anxiety, and depression
| العنوان: | The testing for COVID-19 in symptomatic patients as a protective factor against stress, anxiety, and depression |
|---|---|
| المؤلفون: | Alan Chaves dos Santos, Gustavo Fonseca de Albuquerque Souza, Alex Sandro Rolland Souza, Gabriella de Almeida Figueredo Praciano, Elias Almeida S. Barbosa, Paula Jaeger Tenorio, Gabriela Oliveira Lobo Pereira da Costa, Laura Brito Barreto Maranhão, Gabriela Albuquerque Souza |
| المصدر: | Revista Brasileira de Saúde Materno Infantil Revista Brasileira de Saúde Materno Infantil v.21 suppl.1 2021 Instituto de Medicina Integral Prof. Fernando Figueira (IMIPFF) instacron:IMIPFF |
| بيانات النشر: | FapUNIFESP (SciELO), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Population, Protective factor, Anxiety, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Stress (linguistics), medicine, 030212 general & internal medicine, Social isolation, education, Depression (differential diagnoses), 030304 developmental biology, 0303 health sciences, education.field_of_study, Depression, business.industry, Public Health, Environmental and Occupational Health, COVID-19, Obstetrics and Gynecology, Gynecology and obstetrics, Odds ratio, Mental health, Pediatrics, Perinatology and Child Health, RG1-991, Stress psychological, medicine.symptom, business |
| الوصف: | Objectives: to determine the frequency of stress, anxiety, and depression symptoms in symptomatic patients for COVID-19. To evaluate the associated factors involved in these variants. Methods: between May/June of 2020, it was conducted a prospective cross-section study with symptomatic participants for COVID-19 (n=300). It was applied an online questionnaire and the DASS-21 to evaluate the mental health of participants. Results: it was observed that 28.6%, 29.7% and 27% of the participants showed severe/extreme levels symptoms of stress, anxiety, and depression, respectively. The testing for COVID-19 application had constituted a protective factor for the development of psychiatric morbidity, once it had shown significant association in the low frequencies of severe/extreme depression [Odds Ratio (OR)]= 0.26; p=0.002) and stress (OR=0.39; p=0.01). Conclusion: individuals that are symptomatic for COVID-19 are a vulnerable group that may present high symptomatology for depression, anxiety, and stress. The identification of psychiatric morbidity frequency and its associated factors may contribute for the development of mental health strategies aiming at the prevention and mitigation of psychological impact in COVID-19 symptomatic population during the pandemic. |
| وصف الملف: | text/html |
| تدمد: | 1806-9304 1519-3829 |
| DOI: | 10.1590/1806-9304202100s100007 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a36dbd5434ea4fc91cdd204950ce0c https://doi.org/10.1590/1806-9304202100s100007 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....21a36dbd5434ea4fc91cdd204950ce0c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18069304 15193829 |
|---|---|
| DOI: | 10.1590/1806-9304202100s100007 |